Literature DB >> 19424615

Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis.

Kiyoon Kim1, Miran Yu, Seulhee Han, Inkyung Oh, Young-Jun Choi, Sungsoo Kim, Kyungsik Yoon, Minhyung Jung, Wonchae Choe.   

Abstract

Despite considerable progress in understanding the function of peroxiredoxin (Prx) in cancer, its expression patterns have not been extensively studied in response to cervical carcinogenesis. We evaluated the expression of Prx isoforms in normal tissue, cervical intraepithelial neoplasia (CIN1, CIN2, and CIN3), and cervical cancer. We found strong pattern of increased Prx II and III immunostaining with increasing severity of the lesion. No difference in staining intensity by grade of lesion was observed for Prx I, and IV. Therefore, we conclude that Prx II and III are upregulated in response to the development of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424615

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  25 in total

Review 1.  The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells.

Authors:  Lianqin Li; Ai-Qun Yu
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-21       Impact factor: 4.553

2.  Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4.

Authors:  Anamika Basu; Hiya Banerjee; Heather Rojas; Shannalee R Martinez; Sourav Roy; Zhenyu Jia; Michael B Lilly; Marino De León; Carlos A Casiano
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

3.  High-Protein Intake during Weight Loss Therapy Eliminates the Weight-Loss-Induced Improvement in Insulin Action in Obese Postmenopausal Women.

Authors:  Gordon I Smith; Jun Yoshino; Shannon C Kelly; Dominic N Reeds; Adewole Okunade; Bruce W Patterson; Samuel Klein; Bettina Mittendorfer
Journal:  Cell Rep       Date:  2016-10-11       Impact factor: 9.423

4.  Polymorphisms of peroxiredoxin 1, 2 and 6 are not associated with esophageal cancer.

Authors:  Bo Zhang; Kai Wang; Gang He; Xinying Guan; Botao Liu; Yangbo Liu; Yun Bai
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-04       Impact factor: 4.553

5.  PRDX2 protects hepatocellular carcinoma SMMC-7721 cells from oxidative stress.

Authors:  Silei Zhou; Quanli Han; Ru Wang; Xin Li; Qingyang Wang; Huizhong Wang; Jing Wang; Yuanfang Ma
Journal:  Oncol Lett       Date:  2016-07-21       Impact factor: 2.967

6.  Prognostic biomarkers for HNSCC using quantitative real-time PCR and microarray analysis: β-tubulin isotypes and the p53 interactome.

Authors:  Sharon Lobert; Mary E Graichen; Robert D Hamilton; Karen T Pitman; Michael R Garrett; Chindo Hicks; Tejaswi Koganti
Journal:  Cytoskeleton (Hoboken)       Date:  2014-11-22

7.  Expression and prognostic significance of human peroxiredoxin isoforms in endometrial cancer.

Authors:  Seulhee Han; Haiying Shen; Minhyung Jung; Bum-Soo Hahn; Byung Kwan Jin; Insug Kang; Joohun Ha; Wonchae Choe
Journal:  Oncol Lett       Date:  2012-03-16       Impact factor: 2.967

8.  Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer.

Authors:  Xin-yan Wang; Hai-jiao Wang; Xiu-qin Li
Journal:  Tumour Biol       Date:  2013-04-06

9.  Peroxiredoxin 3 is a novel marker for cell proliferation in cervical cancer.

Authors:  Jing-Xia Hu; Qun Gao; Lianqin Li
Journal:  Biomed Rep       Date:  2012-11-29

10.  The critical role of peroxiredoxin-2 in colon cancer stem cells.

Authors:  Linglong Peng; Yongfu Xiong; Rong Wang; Ling Xiang; He Zhou; Zhongxue Fu
Journal:  Aging (Albany NY)       Date:  2021-03-26       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.